FISH ANALYSIS, IGH/BCL2 TRANSLOCATION
Pseudonyms: t(14;18); 14;18 translocation; IGH-BCL2 fusion; IGH-BCL2 translocation; Follicular Lymphoma; Diffuse Large Cell Lymphoma; Lymphoproliferative disorders
TURNAROUND TIME: 7 to 10 days
TESTING METHODOLOGY: Fluorescence in situ hybridization
- Collect: 2 mL bone marrow aspirate in sodium heparin (green); 5 mL peripheral blood in sodium heparin (green) also acceptable
- Minimum Collection: 1 mL bone marrow or 2 mL peripheral blood
- Transport: bone marrow or peripheral blood in sodium heparin (green) at 20-25°C; specimen should arrive in the laboratory within 24 hours of collection
- Stability: Ambient: 24 hours; Refrigerated: 24 hours; Frozen: unacceptable
- Unacceptable Conditions: Frozen or clotted specimens; paraffin-embedded specimens; specimens; in anticoagulants other than sodium heparin
A Cytogenetics/FISH Laboratory Test Requisition must accompany the specimen. Contact the Cytogenetics Laboratory at 918-502-1722 to obtain further information.
Test Summary: Test can detect the 14;18 translocation observed in some cases of follicular lymphoma, diffuse large cell lymphomas and other lymphoproliferative disorders.
Methods: A dual-color dual-fusion FISH analysis performed on interphase cells using a probe for the immunoglobulin heavy chain (IGH) gene on chromosome 14q32 and the BCL2 gene on chromosome 18q21; analysis of 200 interphase cells; analysis of 500 interphase cells for minimal residual disease assessment.
Interpretation: A positive result (IGH/BCL2 fusion) is reported when the percent of cells with an abnormality exceeds the normal reference range for the probes. The detection of an abnormal clone indicates the presence of an abnormal clone with the 14;18 translocation. A negative result indicates no 14;18 translocation was observed but does not rule out the presence of a neoplastic disorder.
FDA Approval: This test is not approved by the FDA and it should be used as an adjunct to clinical and pathological information.
Indications for Use:
- Detection of an abnormal clone in patients with follicular lymphoma, diffuse large cell lymphomas and other lymphoproliferative disorders.
- Monitor the response to therapy using the 14;18 translocation (IGH/BCL2 fusion)
- Detection of minimal residual disease in patients with a 14;18 translocation.